{
    "root": "4ee49cc8-55ca-4274-9ea6-70d7891d8853",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Buprenorphine HCl",
    "value": "20250328",
    "ingredients": [
        {
            "name": "BUPRENORPHINE HYDROCHLORIDE",
            "code": "56W8MW3EN1",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_652822"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM CITRATE, UNSPECIFIED FORM",
            "code": "1Q73Q2JULR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53258"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "buprenorphine sublingual tablets indicated treatment opioid dependence preferred induction . buprenorphine sublingual tablets used part complete treatment plan include counseling psychosocial support .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 administer buprenorphine sublingual tablets sublingually single daily dose . ( 2.1 ) \u2022 strongly consider prescribing naloxone time buprenorphine sublingual tablets initiated renewed patients treated opioid disorder potential relapse , putting risk opioid overdose ( 2.2 ) \u2022 avoid precipitating withdrawal , induction buprenorphine sublingual tablets undertaken objective clear signs withdrawal evident . ( 2.3 ) \u2022 buprenorphine naloxone sublingual film buprenorphine naloxone sublingual tablets generally initiated two days buprenorphine sublingual tablet titration . ( 2.4 ) \u2022 administer buprenorphine sublingual tablets directed full prescribing information . ( 2.3 , 2.4 , 2.5 ) \u2022 buprenorphine sublingual tablets must administered whole . cut , chew , swallow buprenorphine sublingual tablets . ( 2.5 ) \u2022 discontinuing treatment , gradually taper avoid signs symptoms withdrawal . ( 2.9 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "buprenorphine sublingual tablets 8 mg , supplied white , flat faced , beveled-edge tablets product identification `` 54 \u201d \u201c 411 `` one side plain side . ndc 71335-1163-0 : 120 tablets bottle ndc 71335-1163-1 : 90 tablets bottle ndc 71335-1163-2 : 60 tablets bottle ndc 71335-1163-3 : 30 tablets bottle ndc 71335-1163-4 : 20 tablets bottle ndc 71335-1163-5 : 7 tablets bottle ndc 71335-1163-6 : 28 tablets bottle ndc 71335-1163-7 : 1 tablets bottle ndc 71335-1163-8 : 12 tablets bottle ndc 71335-1163-9 : 14 tablets bottle storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature . ] dispense tight , light-resistant container defined usp . store buprenorphine sublingual tablets securely dispose properly [ patient counseling information ( 17 ) ] . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "buprenorphine sublingual tablets contraindicated patients history hypersensitivity buprenorphine , serious , including anaphylactic shock , reported [ ( 5.9 ) ] .",
    "indications_original": "Buprenorphine Sublingual Tablets are indicated for the treatment of opioid dependence and are preferred for induction. Buprenorphine Sublingual Tablets should be used as part of a complete treatment plan to include counseling and psychosocial support.",
    "contraindications_original": "\u2022 Administer Buprenorphine Sublingual Tablets sublingually as a single daily dose. ( 2.1 ) \u2022 Strongly consider prescribing naloxone at the time Buprenorphine Sublingual Tablets are initiated or renewed because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose ( 2.2 ) \u2022 To avoid precipitating withdrawal, induction with Buprenorphine Sublingual Tablets should be undertaken when objective and clear signs of withdrawal are evident. ( 2.3 ) \u2022 Buprenorphine and naloxone sublingual film or buprenorphine and naloxone sublingual tablets are generally initiated after two days of Buprenorphine Sublingual Tablet titration. ( 2.4 ) \u2022 Administer Buprenorphine Sublingual Tablets as directed in the Full Prescribing Information. ( 2.3 , 2.4 , 2.5 ) \u2022 Buprenorphine Sublingual Tablets must be administered whole.  Do not cut, chew, or swallow Buprenorphine Sublingual Tablets. ( 2.5 ) \u2022 When discontinuing treatment, gradually taper to avoid signs and symptoms of withdrawal. ( 2.9 )",
    "warningsAndPrecautions_original": "Buprenorphine Sublingual Tablets\n                  8 mg, supplied as white, flat faced, beveled-edge tablets with product identification \"54\u201d over \u201c411\" on one side and plain on the other side.\n                  \n                  \n                     NDC 71335-1163-0: 120 Tablets in a BOTTLE\n                     NDC 71335-1163-1: 90 Tablets in a BOTTLE\n                     NDC 71335-1163-2: 60 Tablets in a BOTTLE\n                     NDC 71335-1163-3: 30 Tablets in a BOTTLE\n                     NDC 71335-1163-4: 20 Tablets in a BOTTLE\n                     NDC 71335-1163-5: 7 Tablets in a BOTTLE\n                     NDC 71335-1163-6: 28 Tablets in a BOTTLE\n                     NDC 71335-1163-7: 1 Tablets in a BOTTLE\n                     NDC 71335-1163-8: 12 Tablets in a BOTTLE\n                     NDC 71335-1163-9: 14 Tablets in a BOTTLE\n                  \n                  Storage\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]\n                  Dispense in a tight, light-resistant container as defined in USP.\n                  Store Buprenorphine Sublingual Tablets securely and dispose of properly [see Patient Counseling Information (17)].\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Buprenorphine Sublingual Tablets are contraindicated in patients with a history of hypersensitivity to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been reported [see Warnings and Precautions (5.9)].",
    "drug": [
        {
            "name": "Buprenorphine HCl",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3216"
        }
    ]
}